Core Viewpoint - Precipio, Inc. has introduced the Bloodhound BCR::ABL1 assay, the first assay capable of simultaneously detecting and quantifying all four clinically relevant BCR::ABL1 isoforms for Chronic Myeloid Leukemia (CML), setting a new standard for patient monitoring [1][2]. Group 1: Assay Features and Benefits - The Bloodhound BCR::ABL1 assay allows for comprehensive monitoring of disease progression by providing multiple data points from a single test, which is crucial as 25% of patients may have multiple BCR::ABL1 breakpoints that could be missed with traditional testing methods [3]. - This assay establishes a new standard for full quantification of BCR::ABL breakpoints, enabling clinicians to monitor treatment impact and detect early relapse with precise measurements [3][4]. - The assay demonstrates high sensitivity, capable of detecting changes as low as 1 in 100,000 cells (0.001%), which is essential for monitoring measurable residual disease (MRD) [4]. Group 2: Market Position and Innovation - Precipio's Bloodhound assay is the only clinical assay that can test multiple BCR::ABL1 isoforms simultaneously, eliminating the need for separate tests and enhancing laboratory workflow [5][6]. - The assay simplifies the testing process into one standardized test that can be run in various laboratory settings, including physician office laboratories and hospitals, thus improving accessibility [2][7]. - Precipio aims to address the issue of cancer misdiagnosis through innovative diagnostic products, ultimately improving patient outcomes and reducing healthcare costs [8].

Core Insights - Veracyte, Inc. is a leading company in the cancer diagnostics field, specializing in advanced genomic tests for cancer diagnosis and treatment, with notable product lines like Decipher and Afirma [1] Financial Performance - On February 25, 2026, Veracyte reported an earnings per share (EPS) of $0.50, exceeding the estimated EPS of $0.40, indicating effective management and higher profit generation [2][6] - The company's revenue reached approximately $140.6 million, surpassing the anticipated $135.8 million, highlighting the growth of its Decipher and Afirma product lines [2][6] Market Position and Growth - In the last quarter of 2025, Veracyte served over 45,000 patients with its core testing services, demonstrating its ability to expand market presence and deliver valuable diagnostic solutions [3] - The company has a price-to-earnings (P/E) ratio of approximately 42.62, reflecting market confidence in its earnings potential [4] Financial Health - Veracyte has a low debt-to-equity ratio of 0.03, indicating minimal reliance on debt financing, and a strong current ratio of 8.15, suggesting robust liquidity [5] - The enterprise value to sales ratio is around 4.84, and the enterprise value to operating cash flow ratio is approximately 18.35, providing a comprehensive view of its valuation relative to sales and cash flow [4]

Core Viewpoint - Veracyte, Inc. is set to release its financial results for the fourth quarter and full year of 2025 on February 25, 2026, and anticipates significant revenue growth compared to the previous year [1]. Financial Results - For the fourth quarter of 2025, Veracyte expects total revenue to be between $138 million and $140 million, reflecting an increase of 16% to 18% compared to the same period in 2024 [1]. Upcoming Events - The company will host a conference call and webcast on February 25, 2026, at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update [1]. - Veracyte will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 9:45 a.m. Pacific Time [1]. - The company is also scheduled to participate in the Wolfe Research Healthcare Conference and the Jefferies Global Healthcare Conference in November 2025 [1].

Core Insights - AccuStem Sciences, Inc. has initiated a pilot study agreement with NSABP to evaluate the StemPrintER test in a subset of patients from the B-32 cohort, aiming to confirm its predictive capabilities across the full study cohort [1][3] Group 1: StemPrintER Test - The StemPrintER test analyzes 20 genes to stratify early-stage breast cancer patients based on their recurrence risk, measuring the "stemness" of tumors, which may indicate cancer progression and treatment response [2] - Patients with "High Stemness" are up to 4 times more likely to experience distant recurrence compared to "Low Stemness" patients, highlighting the test's prognostic utility [2] Group 2: Collaboration and Study Details - The partnership with NSABP aims to validate preliminary findings that suggest StemPrintER has predictive utility in surgical settings, which could significantly impact surgical planning for breast cancer patients [3][4] - The NSABP B-32 trial, which enrolled over 5,000 patients from 1999 to 2004, demonstrated that sentinel lymph node resection (SLNR) is equivalent to full axillary lymph node dissection (ALND) in terms of overall survival while resulting in fewer side effects [3] Group 3: Company Vision and Goals - AccuStem is focused on optimizing outcomes and quality of life for cancer patients through proprietary molecular testing that addresses unmet clinical needs from screening to treatment [5] - The company believes that by exploring novel disease pathways like tumor "stemness," its tools will enhance understanding of cancer biology, leading to more informed decision-making in patient care [5]

Core Insights - Precipio, Inc. is set to present findings from a joint study with Memorial Sloan Kettering Cancer Center, highlighting the positive impacts of its BCR::ABL1 assay on patient care [1][2] Group 1: Study Findings - The comprehensive study involved 895 patient samples and demonstrated superior performance of the BCR::ABL1 assay, showing concordance with two other leading platforms [2] - The study indicates clear, positive impacts on patient care and significant improvements in laboratory workflows [2] Group 2: Company Overview - Precipio is a healthcare biotechnology company focused on cancer diagnostics, aiming to address cancer misdiagnoses through innovative diagnostic products and services [3] - The company's mission includes delivering higher accuracy and improved laboratory workflow, ultimately leading to better patient outcomes and reduced healthcare expenses [3]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive has a strong focus on technology adoption, utilizing decades of expertise and experience among its content creators [4] - The company employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Company Overview - Precipio, Inc. is a healthcare biotechnology company focused on cancer diagnostics, aiming to address cancer misdiagnoses through innovative diagnostic products and services [3] - The company's mission includes delivering higher accuracy, improving laboratory workflow, and enhancing patient outcomes, which ultimately reduces healthcare expenses [3] Upcoming Corporate Update - Precipio will host its Q3-2025 corporate update call on November 17, 2025, at 5:00 PM ET, providing updates on its current core businesses [1] - Interested listeners can submit questions in advance via email, and a replay of the call will be available approximately 24 hours after the event [2] Communication Channels - Precipio encourages stakeholders to visit its website and follow its social media channels for updates, disclosures, and other material information [4]

Financial Performance - Total revenue in 3Q25 reached $851 million, a 20% year-over-year increase[5] - Adjusted EBITDA in 3Q25 was $135 million, up 37% year-over-year[5] - Core revenue grew by 20% in 3Q25[7] - Screening revenue increased by 22% from $545 million in 3Q24 to $666 million in 3Q25[8] - Precision Oncology core revenue increased by 12% from $163 million in 3Q24 to $183 million in 3Q25[8] - Adjusted EBITDA margin improved to 16% in 3Q25, a 200 basis points increase from 14% in 3Q24[11] Guidance Update - Total revenue guidance for 2025 was updated to $3220-$3235 billion, an increase of $78 million at the midpoint[13] - Screening revenue guidance for 2025 was updated to $2510-$2520 billion, an increase of $60 million at the midpoint[13] - Precision Oncology revenue guidance for 2025 was updated to $710-$715 million, an increase of $18 million at the midpoint[13] - Adjusted EBITDA guidance for 2025 was updated to $470-$480 million, an increase of $10 million at the midpoint[13]

Core Viewpoint - Precipio, Inc. has reported continued revenue growth across its divisions, improved gross margins, and is on track to achieve cash flow positivity and a debt-free balance sheet by the end of 2025 [2][3]. Financial Performance - Q2-2025 revenues reached $5.7 million, a 27% increase year-over-year from $4.4 million in Q2-2024, and a 15% increase quarter-over-quarter from Q1-2025 [7]. - Pathology Services revenue increased by approximately $0.75 million, or 17%, from $4.25 million in Q1-2025 to $5.0 million in Q2-2025 [6]. - Adjusted EBITDA for Q2-2025 was ($78,000), a significant improvement of 87% compared to ($609,000) in Q2-2024 [7]. Products Division - The Products Division experienced a strong rebound in revenues, driven by the return of two customers to full operational volume and the onboarding of a new customer [4]. - Organic revenue growth was noted from existing customers expanding their test offerings with new HemeScreen panels [5]. Pathology Services Division - The Pathology Services Division achieved revenue growth through the acquisition of new customers and increased volume from existing customers, with no substantial capital expenditures anticipated to support this growth [6]. - Gross margins for the Pathology Services Division increased year-over-year from 37% to 43% due to increased case volume and a more profitable case mix [8]. Gross Margins and Operating Expenses - Overall gross margins improved year-over-year from 39% to 43% [9]. - Product division gross margins were 44% in Q2-2025, down from 50% in Q2-2024, attributed to increased rent and depreciation expenses due to expansion and equipment purchases [8]. Cash Flow and Debt Management - Cash used by operations decreased from $516,000 in Q2-2024 to $148,000 in Q2-2025, marking a 71% improvement year-over-year [7]. - The company is expected to complete the repayment of the Change Healthcare loan by the end of the year, contributing to a strong balance sheet [2]. Future Outlook - Management believes the company is on track to end the year as a cash flow positive business with a strong balance sheet [2]. - A quarterly shareholder call is scheduled for August 14, 2025, to provide further details on performance and outlook [12].

Core Insights - Precipio, Inc. reported strong financial performance in Q1-2025, with a 43% year-over-year revenue increase, reaching $4.9 million [9][10] - The company anticipates continued revenue growth and a return to positive operating cash flow by Q2 or Q3 of 2025, driven by momentum in its Product business and expanded reimbursement opportunities in Pathology Services [2][8] Financial Performance - Q1-2025 revenues increased by 43% year-over-year, but decreased by 9.5% from Q4-2024 due to seasonal factors and onboarding delays [9] - Adjusted EBITDA improved significantly to ($108K) from ($1,409K) year-over-year, marking a 92% improvement [9] - Cash used in operations decreased to ($44K) in Q1-2025 from ($667K) in Q1-2024, an improvement of 93% [9] Product Division Highlights - The Products Division onboarded one new customer and launched two new panels in Q1-2025, with expectations for increased orders in Q2 [5] - Gross margins for the Products Division increased from 37% to 51% year-over-year [10] Pathology Services Division Highlights - Pathology Services revenues grew 54% year-over-year, with test volume increasing by 46% [7] - The division received MolDx approval for NGS testing, allowing Medicare billing, which is expected to positively impact future revenues [7] Operational Efficiency - Operating expenses as a percentage of net revenue decreased from 87% to 61% year-over-year, with management maintaining flat operating expenses at approximately $3 million per quarter [9] - Overall gross margins improved from 27% to 43% year-over-year, with expectations for continued growth as the revenue mix shifts towards more product sales [10]